Renaissance Capital logo

InflaRx Priced, Nasdaq: IFRX

Developing an antibody for rare autoimmune and inflammatory diseases.

Industry: Health Care

Latest Trade: $3.25 0.00 (0.0%)

First Day Return: -0.1%

Return from IPO: -78.3%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on applying our proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Our lead product candidate, IFX-1, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. We are developing IFX-1 for the treatment of HS, a chronic debilitating systemic inflammatory skin disease, for which we plan to initiate a Phase IIb clinical trial in the 1Q18. Beyond HS, we intend to develop IFX-1 and other proprietary antibodies to address a wide array of complement-mediated diseases with significant unmet needs, including AAV, a rare, life-threatening autoimmune disease.
more less
IPO News for InflaRx
more
IPO Data
IPO File Date 10/13/2017
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 6.7
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 11/07/2017
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 6.7
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Jena, Germany
Founded 2007
Employees 17
Website www.inflarx.com